Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5632087 | 0.90 | DPP4 (0.37) | DPP4DPP7PPARGPPARAACE | |
| SCHEMBL5219023 | 0.85 | DPP4 (0.52) | DPP4DPP7PPARGPPARAFAP | |
| SCHEMBL5632086 | 0.83 | DPP4 (0.42) | DPP4DPP7PPARGPPARAACE | |
| SCHEMBL5220123 | 0.75 | DPP4 (0.61) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL6828636 | 0.74 | DPP4 (0.75) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL3150545 | 0.74 | DPP4 (0.75) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL14572688 | 0.72 | DPP4 (0.70) | DPP4DPP7FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5224457 | 0.71 | DPP4 (0.69) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL13770774 | 0.67 | PPARG (0.53) | DPP4DPP7PPARGPPARAACE | |
| SCHEMBL9784957 | 0.66 | ALDH1A1 (0.51) | DPP4DPP7PPARGPPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399420-B1 | PYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20040167341-A1 | Pyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167341-A1 | Pyrrolidines as dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885PPARG 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.